BRIUMVI momentum pushes TG Therapeutics to a billion dollar guide
- BRIUMVI is the whole story today, delivering $233 million of U.S. net product revenue in Q3 2026.
- Management raised full-year 2026 global revenue guidance to $1 billion.
- Treatment-naive patients now make up nearly 40 percent of new patient starts, indicating strong early adoption.
- The main risk remains concentration, as one drug faces much larger rivals like Roche and Genentech.
- Positive clinical data paves the way for a simpler single starting dose and a potential future version given under the skin.
A great launch pushing high expectations
TG Therapeutics is a focused biotech with one major product, BRIUMVI. The drug treats relapsing forms of multiple sclerosis, often called RMS. The third quarter of 2026 was exceptionally strong. U.S. BRIUMVI net product revenue hit $233 million, pushing global revenue to approximately $260 million for the quarter.
Management lifted full-year 2026 global revenue guidance to $1 billion, with U.S. revenue expected to fall between $915 million and $920 million. The company expects to exit the year above a $1 billion annualized run rate, fueled by record new patient starts.
The bull case relies on BRIUMVI expanding its share in the anti-CD20 market for MS. Its one-hour infusion is easy to explain to doctors and patients. The pipeline also supports the story. At the recent ECTRIMS meeting, the company shared positive seven-year follow-up data, success in a trial testing a simpler starting dose, and strong early data for a version of the drug injected under the skin.
The bear case is simple concentration. This is still a one-product company, and it competes with giants like Roche and Genentech. The Finn view notes that valuation risks remain. As the company crosses the billion-dollar threshold and takes on more debt, the stock requires flawless execution to keep climbing.
One MS drug funds the company
TG Therapeutics makes money by selling BRIUMVI in the United States and global markets. The drug is distributed mainly through specialty pharmacies and given in infusion centers. Its key pitch is that it offers an effective anti-CD20 MS therapy with a fast one-hour infusion time.
The company runs as a single business segment. Growth comes from adding new patients, keeping existing patients on the drug, and winning share from older therapies. Cash from BRIUMVI goes toward expanding the commercial effort and funding studies that could improve the drug label.
The company recently entered a new five-year credit facility. This $750 million senior secured credit facility brought in capital and allowed management to increase its share repurchase authorization to $300 million.
That capital plan works well while sales climb. However, more debt means the financial story is less forgiving if BRIUMVI growth slows down or if competitors win back market share.
BRIUMVI and ways to extend it
BRIUMVI IV for relapsing MS
This is the approved product and the core business. It generated $233 million of U.S. net product revenue in Q3 2026.
ENHANCE single-day starting dose
This study tested whether the first two IV starting doses can be combined into one. The trial met its endpoint and targets a mid-2027 label update.
Subcutaneous BRIUMVI
This formulation would let patients receive the drug under the skin. After positive Phase 1 data, the company expects pivotal Phase 3 data around year-end 2026 or early 2027.
Azer-cel
Azer-cel is an off-the-shelf CD19 CAR T-cell therapy being studied in progressive forms of MS, showing early safety and stability in Phase 1 trials.
Myasthenia gravis study
The company is exploring BRIUMVI in myasthenia gravis with ongoing Phase 2 studies.
Treatment-resistant schizophrenia study
This is an early exploratory effort outside the core MS market. It could broaden the company over time, but it is not central to near-term revenue.
Mostly U.S. BRIUMVI sales
TG Therapeutics reports one operating segment. For Q3 2026, the company generated $233 million in U.S. BRIUMVI net product revenue out of approximately $260 million globally, making the U.S. business roughly 90 percent of the total.
What could break the thesis
BRIUMVI slowdown
High impact · Medium oddsThe company depends heavily on one drug. If new starts slow, if patients stop therapy sooner than expected, or if payers tighten access, the raised 2026 guide could come under pressure. Expectations are now very high.
Roche and Genentech pressure
High impact · High oddsTGTX competes in the anti-CD20 MS market against much larger companies with deep sales reach. BRIUMVI has a clear convenience pitch, but rivals can respond with contracting, doctor outreach, or better delivery options.
Subcutaneous data disappoints
Medium impact · Medium oddsA version injected under the skin could help BRIUMVI compete for patients who prefer at-home dosing. If the pivotal Phase 3 data is weak, that expansion path becomes less valuable. The IV franchise would remain important, but overall growth would slow.
Debt limits flexibility
Medium impact · Medium oddsThe new $750 million senior secured credit facility gives TG more capital and supports buybacks, but it increases debt. If revenue stalls, interest costs and repayment needs could limit research spending.
Manufacturing or tariff shock
Medium impact · Low oddsBRIUMVI is currently manufactured in South Korea. Management does not expect a material hit from currently proposed tariffs because the cost of goods is low. Still, a supply issue could hurt margins.
In one breath
What does TG Therapeutics sell?
TG Therapeutics sells BRIUMVI, also called ublituximab. It is an anti-CD20 monoclonal antibody used to treat relapsing forms of multiple sclerosis.
Why did TGTX raise its 2026 guidance again?
The company reported $233 million of U.S. BRIUMVI net product revenue in Q3 2026. Management pointed to record new patient enrollments and treatment-naive patients making up nearly 40 percent of new starts.
What are the biggest upcoming catalysts for TGTX?
The company expects pivotal Phase 3 data for subcutaneous BRIUMVI around year-end 2026 or early 2027. It also expects a potential FDA approval for the simplified ENHANCE single-day starting dose by mid-2027.
Is TG Therapeutics profitable?
The internal view treats the company as solidly profitable after the BRIUMVI launch scaled, generating $86 million in Q3 operating income. The key question is whether profit growth can keep pace with debt, buybacks, and pipeline spending.
Sources and research notes
This page combines Finn's company research with public filings and other cited materials. The thesis is reviewed when material company information changes; Finn Scores use the latest available scoring data.
- Thesis reviewed
- November 15, 2026
- Score data
- November 15, 2026
- Reviewed by
- Shivam Bharuka
Comparable Biotechnology companies
Companies near TG Therapeutics, Inc. in Finn's Biotechnology industry ranking.

